Neurocrine Biosciences, Inc. (NASDAQ:NBIX)‘s stock had its “outperform” rating restated by equities research analysts at Leerink Swann in a research note issued on Tuesday. They presently have a $72.00 price target on the stock, up from their prior price target of $67.00. Leerink Swann’s price target suggests a potential upside of 16.39% from the stock’s previous close. Leerink Swann also issued estimates for Neurocrine Biosciences’ Q3 2017 earnings at ($0.50) EPS, Q4 2017 earnings at ($0.40) EPS, FY2017 earnings at ($2.48) EPS and FY2018 earnings at ($2.10) EPS.

A number of other research firms also recently issued reports on NBIX. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $70.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 7th. BidaskClub upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. ValuEngine upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Robert W. Baird restated an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $58.00 price target on shares of Neurocrine Biosciences in a research note on Sunday, September 17th. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $68.81.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The business had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same period last year, the business posted ($0.46) earnings per share.

COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/12/neurocrine-biosciences-inc-nbix-stock-rating-reaffirmed-by-leerink-swann.html.

In other news, insider Haig P. Bozigian sold 26,250 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the sale, the insider now directly owns 144,601 shares of the company’s stock, valued at approximately $8,676,060. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher Flint Obrien sold 6,925 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total value of $422,702.00. Following the sale, the insider now directly owns 55,898 shares in the company, valued at $3,412,013.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 132,580 shares of company stock worth $7,440,850. 4.80% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Ardsley Advisory Partners purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $230,000. Davidson Kempner Capital Management LP purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $3,639,000. Asymmetry Capital Management L.P. purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $1,565,000. Nomura Holdings Inc. purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $466,000. Finally, Bank of Nova Scotia purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $1,849,000.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.